Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
Aaron Guanliang LimChrister Frode AasEge Su ÇağlarJørn Henrik VoldLars Thore FadnesPeter VickermanKjell Arne JohanssonPublished in: Addiction (Abingdon, England) (2023)
Integrated hepatitis C virus treatment for people who inject drugs in community settings is likely cost-effective compared with standard-of-care referral pathways in Norway and may be cost-saving in settings with particular characteristics.